What is Bicara Therapeutics's stock-based comp?

Bicara Therapeutics (BCAX) reported stock-based comp of $5.86M in Q1 2026.

How has Bicara Therapeutics's stock-based comp changed year-over-year?

Bicara Therapeutics's stock-based comp increased by 69.7% year-over-year, from $3.45M to $5.86M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Bicara Therapeutics BCAX Stock-Based Comp

Stock-Based Comp at other companies

Eli LillyLLY

$161M+4.5%

AmgenAMGN

$75M-11.8%

ArriVent BioPharma, Inc.AVBP

$5.49M+142%

ImmunomeIMNM

$7.95M+39.5%

Arcus BiosciencesRCUS

$19M+18.8%

Syndax PharmaceuticalsSNDX

$12.05M+16.1%

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's stock-based comp?: Bicara Therapeutics (BCAX) reported stock-based comp of $5.86M in Q1 2026.
How has Bicara Therapeutics's stock-based comp changed year-over-year?: Bicara Therapeutics's stock-based comp increased by 69.7% year-over-year, from $3.45M to $5.86M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.